

UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of April 2022

Commission File Number: 001-39545

**Orphazyme A/S**  
(Translation of registrant's name into English)

---

Ole Maaløes Vej 3, DK-2200  
Copenhagen N  
Denmark  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**INCORPORATION BY REFERENCE**

This Report on Form 6-K (the "Report") and Exhibit 99.1 and Exhibit 99.2 to this Report shall be deemed to be incorporated by reference into the registration statements of Orphazyme A/S (the "Company") on Form S-8 (File nos. 333-249407 and 333-255661) and Form F-3 (File no. 333-260283) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently furnished.

---

**EXHIBIT LIST**

| <b>Exhibit</b> | <b>Description</b>                                       |
|----------------|--|
| 99.1           | <a href="#">Company announcement dated April 4, 2022</a> |
| 99.2           | <a href="#">Appendix 1B</a>                              |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Orphazyme A/S**

Date: April 4, 2022

By: /s/ Anders Vadsholt

Name Anders Vadsholt  
Title: Chief Executive Officer  
and Chief Financial Officer

**Orphazyme A/S in restructuring****Company announcement**

No. 17/2022

Inside information

Ole Maaløes Vej 3, DK-2200 Copenhagen N

[www.orphazyme.com](http://www.orphazyme.com)

Company Registration No. 32266355

**Correction: Proposal for a statutory restructuring plan**

**Copenhagen, Denmark, April 4, 2022** – Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced that, in respect to company announcement no. 15/2022 dated March 31, 2022, the Company has been made aware of a typographical error in the header of the table included in Appendix 1B regarding the interim set-off balance as of March 11, 2022.

Accordingly, the following correction is made to the header of the table included in Appendix 1B:

Current wording: “Beløb i mio. DKK / DKK million”.

Corrected wording: “Beløb i tusinder DKK / DKK thousand”.

Please find attached the corrected Appendix 1B to the proposal for a statutory restructuring plan. No other changes or corrections have been made to the proposal for a statutory restructuring plan, including appendices.

**For additional information, please contact****Orphazyme A/S in restructuring**

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 2898 9055  
John Sommer Schmidt, Restructuring Administrator +45 8620 7500

**About Orphazyme**

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in Denmark. Orphazyme's shares are listed on Nasdaq Copenhagen (ORPHA).

**About arimoclomol**

Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials. Arimoclomol has received Orphan Drug Designation (ODD) for NPC in the US and EU. Arimoclomol has received Fast-Track Designation (FTD), Breakthrough Therapy Designation (BTD), and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for NPC. On June 17, 2021, Orphazyme received a Complete Response Letter from the FDA regarding its New Drug Application for arimoclomol for the treatment of NPC. The Company plans to request a Type C Meeting with the FDA in Q2 2022.

**Forward-looking statement**

This company announcement may contain certain forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995 and otherwise, including forward-looking statements about the Company's restructuring process. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company's control, including pursuant to regulatory intervention. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Foreløbig modregnet balance for Orphazyme A/S under rekonstruktion pr. 11. marts 2022/Interim set-off balance of Orphazyme A/S in reconstruction 11 March 2022

Beløb i tusind DKK / Thousand DKK

|  | Rekonstruktion/reconstruction  |                              |                         |  |                             | Note | Konkurs/bankruptcy      |  |                             |
|--|--------------------------------|------------------------------|-------------------------|--|-----------------------------|------|-------------------------|--|-----------------------------|
|  | Bogført værdi/<br>booked value | Reguleringer/<br>adjustments | Vurdering/<br>Valuation | Virksomheds pant /Pledge floating charge | Nettoaktiver/<br>net assets |      | Vurdering/<br>Valuation | Virksomheds pant /Pledge floating charge | Nettoaktiver/<br>net assets |
| Udviklingsprojekt/development project - Arimoclomol for NPC  | 0                              | 75.000                       | 75.000                  | -15.916                                  | 59.084                      | 1    | 0                       | 0  |                             |
| Licenser, rettigheder/Licenses, rights   | 1.603                          | -1.603                       | 0                       |  | 0                           | 2    | 0                       | 0  |                             |
| Udskudte skatteaktiver/Deferred tax assets   | 0                              | 0                            | 0                       |  | 0                           | 3    | 0                       | 0  |                             |
| Depositem/Deposits   | 605                            | -303                         | 303                     |  | 303                         | 4    | 0                       | 0  |                             |
| Software/Software  | 450                            | 0                            | 450                     | -450                                     | 0                           | 5    | 0                       |  |                             |
| Andre anlæg og maskiner/Property plant & equipments  | 2.046                          | -1.046                       | 1.000                   | -1.000                                   | 0                           | 6    | 100                     | -100                                     |                             |
| Right of use assets - leasing aktiver  | 3.493                          | -2.743                       | 750                     |  | 750                         | 7    | 750                     | 750                                      |                             |
| Investering i datterselskaber/Investment in subsidiaries   | 2.735                          | -2.735                       | 0                       |  | 0                           | 8    | 0                       | 0  |                             |
| Tilgodehavende i tilknyttede virksomheder/Intercompany receivables   | 9.982                          | -9.982                       | 0                       |  | 0                           | 9    | 0                       | 0  |                             |
| Tilgodehavende skattefordringer/ Tax receivable R&D  | 8.250                          | 2.750                        | 11.000                  |  | 11.000                      | 10   | 5.500                   | 5.500                                    |                             |
| Forudbetalte omkostninger/Prepaid expenses   | 7.374                          | -2.429                       | 4.945                   |  | 4.945                       | 11   | 0                       | 0  |                             |
| Tilgodehavende moms/VAT receivable   | 3.970                          |                              | 3.970                   |  | 3.970                       | 12   | 3.970                   | 3.970                                    |                             |
| Tilgodehavender fra salg/Trade receivables   | 15.111                         | 1.637                        | 16.748                  | -16.748                                  | 0                           | 13   | 16.748                  | -16.748                                  |                             |
| Likvide beholdninger/Cash  | 36.819                         | 291                          | 37.110                  |  | 37.110                      | 14   | 37.110                  | 37.110                                   |                             |
| <b>Ubehæftede aktiver/Assets</b>   | <b>92.438</b>                  | <b>58.838</b>                | <b>151.276</b>          | <b>-34.114</b>                           | <b>117.162</b>              |      | <b>64.178</b>           | <b>-16.848</b>                           | <b>47.330</b>               |
| Anslåede omkostninger der har forrang/Estimated costs ranking prior to other costs:  |                                |                              |                         |  |                             |      |                         |  |                             |
| Boomkostninger/Cost under bankruptcy   |                                |                              |                         |  |                             |      |                         | -7.500                                   |                             |
| Rekonstruktionsomkostninger/Costs of reconstruction  |                                |                              |                         |  | -5.000                      |      |                         | -5.000                                   |                             |
| Anslået driftsunderskud i rekonstruktionen/Estimated covered losses in reconstruction  |                                |                              |                         |  |                             |      |                         | -18.625                                  |                             |
|  |                                |                              |                         |  | 77.162                      |      |                         | 16.205                                   |                             |
| Anslåede opsigelseomkostninger/Estimated payroll termination co  |                                |                              |                         |  | -8.514                      |      |                         | -17.000                                  |                             |
| Anslåede lønmodtager pr. 11. marts 2022 feriepenge og skyldig løn/estimated Employee at 11 Mar., holiday pay and accrued pay |                                | -6.800                       |                         |  | -6.800                      |      |                         | -6.800                                   |                             |
| <b>Anslåede nettoaktiver til usikrede kreditorer/Estimated net assets to unsecured creditors</b>                             |                                |                              |                         |  | <b>61.848</b>               |      |                         | <b>-7.595</b>                            |                             |
| Anslåede akkordkreditorer (simple krav)/Estimated creditors in composition (ordinary claims)                                 | 122.326                        | -5.980                       | 116.346                 | -34.114                                  | 82.232                      |      |                         | 99.498                                   |                             |
| <b>Foreløbig beregnet dividende/Calculated interim dividend</b>  |                                |                              |                         |  | <b>75 %</b>                 |      |                         | <b>0 %</b>                               |                             |
| Akkordkreditorer/Creditors in composition:   |                                |                              |                         |  |                             |      |                         |  |                             |
| Leasingforpligtelser /Lease liabilities  | 4.201                          | -3.493                       | 708                     |  | 708                         |      |                         | 708                                      |                             |
| French EAP program nATU - refund liability 50%   | 43.756                         |                              | 43.756                  |  | 43.756                      |      |                         | 43.756                                   |                             |
| Kreos loan - Virksomheds pant/Pledge floating charge 9m Euro   | 28.938                         | 5.176                        | 34.114                  | -34.114                                  | 0                           |      | -16.848                 | 17.266                                   |                             |
| Leverandørgæld/Trade payables  | 23.073                         | -863                         | 22.210                  |  | 22.210                      |      |                         | 22.210                                   |                             |
| Skyldige omkostninger/accruals   | 3.659                          |                              | 3.659                   |  | 3.659                       |      |                         | 3.659                                    |                             |
| Anden gæld/other liabilities   | 3.658                          |                              | 3.658                   |  | 3.658                       |      |                         | 3.658                                    |                             |
| Intercompany payable Orphazyme GmbH (CH)   | 5.697                          |                              | 5.697                   |  | 5.697                       |      |                         | 5.697                                    |                             |
| Lønmodtager poster, A-skat/Employee liabilities, payroll taxes   | 9.344                          | -6.800                       | 2.544                   |  | 2.544                       |      |                         | 2.544                                    |                             |
|  | 122.326                        | -5.980                       | 116.346                 | -34.114                                  | 82.232                      |      | 0                       | -16.848                                  | 99.498                      |
| Equity reconciliation/Afstemning egenkapital   | 29.888                         |                              |                         |  | -20.385                     |      |                         | -107.093                                 |                             |